This trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.
Patients with adequate liver function and performance status in whom liver-directed therapy and capecitabine would be appropriate are eligible for this clinical trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
34
Undergo SIRT
Given PO
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.
Time frame: ongoing
Efficacy
Time frame: response rate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.